Oura CEO Forecasts Near $2 Billion in Sales by 2026

Oura, the Finnish wearable tech company behind the smart ring revolution, anticipates a significant leap in revenue, projecting close to $2 billion in sales for the upcoming year. CEO Tom Hale shared this bullish outlook during an interview following a substantial $900 million funding round secured in October, underscoring the company’s aggressive expansion strategy and investment in artificial intelligence.

Speaking to CNBC at Web Summit in Lisbon, Portugal, Hale revealed that Oura is on track to achieve $1 billion in sales in 2025, effectively doubling its revenue from 2024. More impressively, the company forecasts even greater growth in 2026. “Next year is certainly going to be a lot more,” Hale stated. “I don’t know if we know exactly how much but, it’ll be north, maybe close to $2 billion.”

This projection represents a substantial increase from a previously suggested sales forecast of over $1.5 billion, signaling Oura’s potential to nearly double its sales volume for the second consecutive year. Industry analysts suggest that this ambitious growth trajectory is fueled by a combination of factors, including the strategic introduction of health features tailored for women, successful international expansion, and the integration of AI-powered insights and coaching.

“I think a big part of that is just that we’ve really hit the market well with health features for women, we’ve expanded internationally, all these things are driving our growth,” Hale explained.

Valued at $11 billion, Oura has reportedly sold over 5.5 million rings since its initial product launch in 2015, with over 2.5 million units sold since June 2024, according to the company’s data. This robust sales performance indicates strong consumer demand for the Oura Ring, which tracks a range of physiological data, including sleep patterns, activity levels, heart rate variability (HRV), and body temperature. The company is betting big on the future of preventative health, integrating features like glucose monitoring and collaborating in blood pressure research.

Hale emphasized Oura’s longstanding commitment to artificial intelligence, asserting that the company has been “AI-forward from the get-go.” He further elaborated on the company’s plans to leverage AI to deliver proactive healthcare solutions. Oura harnesses AI to transform raw data into actionable advice and personalized coaching, assisting users to comprehend their personal metrics. The company has also introduced its proprietary chatbot, Oura Advisor, which Hale likens to a “doctor in your pocket” for answering health-related inquiries.

“One of the things that Oura does particularly well is it generates insights — basically text — for you that helps you understand your metrics,” Hale said. “One the things that we really believe is that we can become like this sort of guardian angel, right, that’s with you all the time and is starting to give you these predictions about your longer-term health.”

Oura’s strategic partnerships have further broadened its ecosystem. A collaboration with Natural Cycles, an FDA-cleared birth control app, introduced fertility tracking functionalities. Moreover, a partnership with Dexcom earlier this year enabled glucose monitoring, while ongoing blood pressure research promises future integration of cardiovascular health insights. These moves reflect Oura’s ambition to become a comprehensive health-tracking and preventative care platform.

While speculation abounds regarding a potential initial public offering (IPO), Hale maintained that there is “no news on an IPO” at this time. However, given the company’s impressive growth trajectory and increasing market valuation, an IPO remains a distinct possibility in the future.